Shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) have received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Brokers have set a 12 month consensus target price of $41.33 for the company and are predicting that the company will post $0.35 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Opiant Pharmaceuticals an industry rank of 61 out of 255 based on the ratings given to related companies.
A number of research firms recently weighed in on OPNT. TheStreet raised shares of Opiant Pharmaceuticals from a “d” rating to a “c-” rating in a research note on Friday, August 30th. Northland Securities restated a “buy” rating and set a $42.00 price target on shares of Opiant Pharmaceuticals in a research note on Thursday, November 7th.
OPNT traded up $0.04 during trading on Friday, reaching $13.51. 12,706 shares of the company’s stock were exchanged, compared to its average volume of 20,593. The company has a market capitalization of $55.32 million, a P/E ratio of -1.90 and a beta of 0.25. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $14.73 and a 200 day moving average price of $13.84. Opiant Pharmaceuticals has a fifty-two week low of $9.98 and a fifty-two week high of $18.23.
Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its quarterly earnings data on Tuesday, November 12th. The technology company reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $1.87. Opiant Pharmaceuticals had a net margin of 24.16% and a negative return on equity of 7.39%. The company had revenue of $20.64 million during the quarter, compared to analysts’ expectations of $5.73 million. As a group, research analysts forecast that Opiant Pharmaceuticals will post 0.23 EPS for the current year.
In related news, insider Phil Skolnick sold 10,000 shares of the stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $14.68, for a total transaction of $146,800.00. Also, Director Michael Sinclair sold 60,000 shares of Opiant Pharmaceuticals stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $12.52, for a total transaction of $751,200.00. Insiders sold a total of 87,143 shares of company stock worth $1,152,216 in the last 90 days. 30.88% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in OPNT. Advisor Group Inc. increased its holdings in shares of Opiant Pharmaceuticals by 24.3% during the second quarter. Advisor Group Inc. now owns 4,600 shares of the technology company’s stock worth $61,000 after buying an additional 900 shares in the last quarter. BlackRock Inc. increased its holdings in Opiant Pharmaceuticals by 93.5% during the 2nd quarter. BlackRock Inc. now owns 20,792 shares of the technology company’s stock valued at $276,000 after purchasing an additional 10,045 shares in the last quarter. Stonepine Capital Management LLC raised its position in Opiant Pharmaceuticals by 7.0% in the 2nd quarter. Stonepine Capital Management LLC now owns 315,468 shares of the technology company’s stock valued at $4,180,000 after purchasing an additional 20,574 shares during the last quarter. Morgan Stanley raised its position in Opiant Pharmaceuticals by 1,000.3% in the 2nd quarter. Morgan Stanley now owns 22,414 shares of the technology company’s stock valued at $297,000 after purchasing an additional 20,377 shares during the last quarter. Finally, Wedge Capital Management L L P NC bought a new position in Opiant Pharmaceuticals in the 3rd quarter valued at $363,000. Hedge funds and other institutional investors own 21.49% of the company’s stock.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
See Also: Return on Investment (ROI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opiant Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.